Libo Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Libo Zhao has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Qi Li
The Second Affiliated Hospital of Anhui Medical University
4 shared publications Xiaoyan Du
Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China
4 shared publications- Peng Xie
NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications Lan Deng
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publicationsQing Tan
Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China; Department of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, Chongqing Medical University, Chongqing, China
2 shared publicationsRui Zhao
Department of Neurology, Yongchuan Hospital of Chongqing Medical University
2 shared publications
Latest Publications
- Open Access
- 21 April 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (4) , e70483
Analysis of the Incidence and Influencing Factors of Depression in the Acute Stage of Ischemic Stroke: A Retrospective Clinical Study
Background: Poststroke depression (PSD) is a common complication following a stroke, but the risk factors for its onset remain controversial. The purpose of this study was to investigate the incidence of PSD and its relationship with stroke sites to provide more evidence for the early identification of high‐risk patients with PSD.Methods: This retrospective clinical study recruited acute ischemic stroke patients and assessed them for 2 weeks after the onset. Blood samples were collected from the patients upon admission for routine blood tests and blood biochemical analysis. Stroke patients with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM‐V) depressive diagnosis were rated for severity using the Hamilton Depression Rating Scale (HAMD), as measured by the National Institutes of Health Stroke Scale (NIHSS). Stroke prognosis was measured by the Modified Rankin Scale (mRS).Results: A total of 192 stroke patients were evaluated. Two weeks after the stroke, 73 patients developed depression, and the incidence of PSD was 38.02%. The proportion of depression composition after 2 weeks was as follows: 63 cases were mild depression, accounting for 91.8%; 6 cases were moderate depression, accounting for 8.2%. In univariate analysis, red blood cell (RBC) count, thalamic infarction, mRS score, and mini‐mental state examination (MMSE) score were identified as risk factors associated with the occurrence of PSD. Multivariate logistic regression analysis further confirmed that RBC count, mRS score, and MMSE score were significantly correlated with PSD development.Conclusion: This study suggests that patients with thalamic infarction and TOAST type I stroke should receive increased clinical attention. RBC count, high mRS scores, and high MMSE scores are three independent risk factors for PSD occurrence.
- 21 April 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (4) , e70483
Open AccessAnalysis of the Incidence and Influencing Factors of Depression in the Acute Stage of Ischemic Stroke: A Retrospective Clinical Study
Background: Poststroke depression (PSD) is a common complication following a stroke, but the risk factors for its onset remain controversial. The purpose of this study was to investigate the incidence of PSD and its relationship with stroke sites to provide more evidence for the early identification of high‐risk patients with PSD.Methods: This retrospective clinical study recruited acute ischemic stroke patients and assessed them for 2 weeks after the onset. Blood samples were collected from the patients upon admission for routine blood tests and blood biochemical analysis. Stroke patients with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM‐V) depressive diagnosis were rated for severity using the Hamilton Depression Rating Scale (HAMD), as measured by the National Institutes of Health Stroke Scale (NIHSS). Stroke prognosis was measured by the Modified Rankin Scale (mRS).Results: A total of 192 stroke patients were evaluated. Two weeks after the stroke, 73 patients developed depression, and the incidence of PSD was 38.02%. The proportion of depression composition after 2 weeks was as follows: 63 cases were mild depression, accounting for 91.8%; 6 cases were moderate depression, accounting for 8.2%. In univariate analysis, red blood cell (RBC) count, thalamic infarction, mRS score, and mini‐mental state examination (MMSE) score were identified as risk factors associated with the occurrence of PSD. Multivariate logistic regression analysis further confirmed that RBC count, mRS score, and MMSE score were significantly correlated with PSD development.Conclusion: This study suggests that patients with thalamic infarction and TOAST type I stroke should receive increased clinical attention. RBC count, high mRS scores, and high MMSE scores are three independent risk factors for PSD occurrence.
- Open Access
- 24 February 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
A Chinese patient with cardiogenic stroke and warfarin resistance: a case report
Warfarin is the most commonly used oral anticoagulant drug in clinical practice due to its effective anticoagulant effect and low cost. Warfarin plays a crucial role in the anticoagulant treatment of patients with thrombotic diseases such as atrial fibrillation, heart valve replacement, and deep vein thrombosis. In general, low-dose warfarin can effectively achieve the optimal international normalized ratio (INR) for patients requiring anticoagulation therapy. In some cases, patients may require significantly higher doses of warfarin to achieve an INR in the desired range; failure to achieve this is commonly referred to as warfarin resistance. We report a rare case of cerebral infarction caused by atrial fibrillation and warfarin resistance in China. A Chinese patient with atrial fibrillation complicated by cerebral infarction had been taking warfarin for 2 years, and the dose was gradually increased to 12.5 mg per day; however, the INR remained below the standard. The patient was considered to be resistant to warfarin. The cause of warfarin resistance in this patient is unknown, but we speculate that pharmacodynamic and genetic factors may be involved. Finally, we chose to replace warfarin with rivaroxaban to avoid the risk of bleeding at high doses. To date, there has been no bleeding or infarcts since the patient was discharged. In cases where the cause of warfarin resistance cannot be determined, alternative drugs may be more appropriate. When considering warfarin resistance, it is important to actively search for the cause of resistance early on. If the cause is determined, appropriate measures should be taken. If the cause is not determined or cannot be resolved, the dose can be gradually increased under close monitoring, alternatives can be actively adopted, and patients can be informed and educated.
- 24 February 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Open AccessA Chinese patient with cardiogenic stroke and warfarin resistance: a case report
Warfarin is the most commonly used oral anticoagulant drug in clinical practice due to its effective anticoagulant effect and low cost. Warfarin plays a crucial role in the anticoagulant treatment of patients with thrombotic diseases such as atrial fibrillation, heart valve replacement, and deep vein thrombosis. In general, low-dose warfarin can effectively achieve the optimal international normalized ratio (INR) for patients requiring anticoagulation therapy. In some cases, patients may require significantly higher doses of warfarin to achieve an INR in the desired range; failure to achieve this is commonly referred to as warfarin resistance. We report a rare case of cerebral infarction caused by atrial fibrillation and warfarin resistance in China. A Chinese patient with atrial fibrillation complicated by cerebral infarction had been taking warfarin for 2 years, and the dose was gradually increased to 12.5 mg per day; however, the INR remained below the standard. The patient was considered to be resistant to warfarin. The cause of warfarin resistance in this patient is unknown, but we speculate that pharmacodynamic and genetic factors may be involved. Finally, we chose to replace warfarin with rivaroxaban to avoid the risk of bleeding at high doses. To date, there has been no bleeding or infarcts since the patient was discharged. In cases where the cause of warfarin resistance cannot be determined, alternative drugs may be more appropriate. When considering warfarin resistance, it is important to actively search for the cause of resistance early on. If the cause is determined, appropriate measures should be taken. If the cause is not determined or cannot be resolved, the dose can be gradually increased under close monitoring, alternatives can be actively adopted, and patients can be informed and educated.
- Open Access
- 31 October 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 952843
The SON2A2 score: A novel grading scale for predicting hemorrhage and outcomes after thrombolysis
Objectives: This study aimed to develop a score including novel putative predictors for predicting the risk of sICH and outcomes after thrombolytic therapy with intravenous (IV) recombinant tissue-type plasminogen activator (r-tPA) in acute ischemic stroke patients.Methods: All patients with acute ischemic stroke treated with IV r-tPA at three university-based hospitals in Chongqing, China, from 2014 to 2019 were retrospectively studied. Potential risk factors associated with sICH (NINDS criteria) were determined with multivariate logistic regression, and we developed our score according to the magnitude of logistic regression coefficients. The score was validated in another independent cohort. Area under the receiver operating characteristic curve (AUC-ROC) was used to assess the performance of the score. Calibration was evaluated using the Hosmer–Lemeshow goodness-of-fit method.Results: The SON2A2 score (0 to 8 points) consisted of history of smoking (no = 1, yes = 0, β = 0.81), onset-to-needle time (≥3.5 = 1,10 = 2, ≤10 = 0, β = 1.22), neutrophil percentage (≥80.0% = 1, 11 = 0, β = 1.30), and age (>65 years = 1, ≤65 years = 0, β = 0.89). The SON2A2 score was strongly associated with sICH (OR 1.98; 95%CI 1.675–2.34) and poor outcomes (OR 1.89; 95%CI 1.68–2.13). AUC-ROC in the derivation cohort was 0.82 (95%CI 0.77–0.86). Similar results were obtained in the validation cohort. The Hosmer–Lemeshow test revealed that predicted and observed event rates in derivation and validation cohorts were very close.Conclusion: The SON2A2 score is a simple, efficient, quick, and easy-to-perform scale for predicting the risk of sICH and outcome after intravenous r-tPA thrombolysis within 4.5 h in patients with ischemic stroke, and risk assessment using this test has the potential for early and personalized management of this disease in high-risk patients.
- 31 October 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 952843
Open AccessThe SON2A2 score: A novel grading scale for predicting hemorrhage and outcomes after thrombolysis
Objectives: This study aimed to develop a score including novel putative predictors for predicting the risk of sICH and outcomes after thrombolytic therapy with intravenous (IV) recombinant tissue-type plasminogen activator (r-tPA) in acute ischemic stroke patients.Methods: All patients with acute ischemic stroke treated with IV r-tPA at three university-based hospitals in Chongqing, China, from 2014 to 2019 were retrospectively studied. Potential risk factors associated with sICH (NINDS criteria) were determined with multivariate logistic regression, and we developed our score according to the magnitude of logistic regression coefficients. The score was validated in another independent cohort. Area under the receiver operating characteristic curve (AUC-ROC) was used to assess the performance of the score. Calibration was evaluated using the Hosmer–Lemeshow goodness-of-fit method.Results: The SON2A2 score (0 to 8 points) consisted of history of smoking (no = 1, yes = 0, β = 0.81), onset-to-needle time (≥3.5 = 1,10 = 2, ≤10 = 0, β = 1.22), neutrophil percentage (≥80.0% = 1, 11 = 0, β = 1.30), and age (>65 years = 1, ≤65 years = 0, β = 0.89). The SON2A2 score was strongly associated with sICH (OR 1.98; 95%CI 1.675–2.34) and poor outcomes (OR 1.89; 95%CI 1.68–2.13). AUC-ROC in the derivation cohort was 0.82 (95%CI 0.77–0.86). Similar results were obtained in the validation cohort. The Hosmer–Lemeshow test revealed that predicted and observed event rates in derivation and validation cohorts were very close.Conclusion: The SON2A2 score is a simple, efficient, quick, and easy-to-perform scale for predicting the risk of sICH and outcome after intravenous r-tPA thrombolysis within 4.5 h in patients with ischemic stroke, and risk assessment using this test has the potential for early and personalized management of this disease in high-risk patients.
- 10 October 2022
- Published by Elsevier in World Neurosurgery
- Vol. 168, e538-e545
Buffer Coefficient as a Predictor of the Prognosis of Massive Cerebral Infarction
- 10 October 2022
- Published by Elsevier in World Neurosurgery
- Vol. 168, e538-e545
Buffer Coefficient as a Predictor of the Prognosis of Massive Cerebral Infarction
- Open Access
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 844434
Altered Visual Cortical Excitability Is Associated With Psychopathological Symptoms in Major Depressive Disorder
Previous studies suggest that in people with major depressive disorder (MDD), there exists a perturbation of the normal balance between the excitatory and inhibitory neurotransmitter systems in the visual cortex, indicating the possibility of altered visual cortical excitability. However, investigations into the neural activities of the visual cortex in MDD patients yielded inconsistent findings. The present study aimed to evaluate the visual cortical excitability utilizing a paired-pulse stimulation paradigm in patients with MDD and to access the paired-pulse behavior of recording visual evoked potentials (VEPs) as a marker of MDD. We analyzed the amplitudes of VEPs and paired-pulse suppression (PPS) at four different stimulus onset asynchronies (SOAs) spanning 93 ms to 133 ms. Further, the relationship between PPS and the symptom severity of depression was investigated using Spearman's correlation. We found that, whereas the first VEP amplitude remained unchanged, the second VEP amplitude was significantly higher in the MDD group compared to the healthy controls. As a result, the amplitude ratio (second VEP amplitude/first VEP amplitude) increased, indicating reduced PPS and thus increased excitability in the visual cortex. Moreover, we found the amplitude ratios had a significantly positive correlation with the symptom severity of depression in MDD, indicating a clinically useful biomarker for MDD. Our findings provide new insights into the changes in the excitation-inhibition balance of visual cortex in MDD, which could pave the way for specific clinical interventions.
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 844434
Open AccessAltered Visual Cortical Excitability Is Associated With Psychopathological Symptoms in Major Depressive Disorder
Previous studies suggest that in people with major depressive disorder (MDD), there exists a perturbation of the normal balance between the excitatory and inhibitory neurotransmitter systems in the visual cortex, indicating the possibility of altered visual cortical excitability. However, investigations into the neural activities of the visual cortex in MDD patients yielded inconsistent findings. The present study aimed to evaluate the visual cortical excitability utilizing a paired-pulse stimulation paradigm in patients with MDD and to access the paired-pulse behavior of recording visual evoked potentials (VEPs) as a marker of MDD. We analyzed the amplitudes of VEPs and paired-pulse suppression (PPS) at four different stimulus onset asynchronies (SOAs) spanning 93 ms to 133 ms. Further, the relationship between PPS and the symptom severity of depression was investigated using Spearman's correlation. We found that, whereas the first VEP amplitude remained unchanged, the second VEP amplitude was significantly higher in the MDD group compared to the healthy controls. As a result, the amplitude ratio (second VEP amplitude/first VEP amplitude) increased, indicating reduced PPS and thus increased excitability in the visual cortex. Moreover, we found the amplitude ratios had a significantly positive correlation with the symptom severity of depression in MDD, indicating a clinically useful biomarker for MDD. Our findings provide new insights into the changes in the excitation-inhibition balance of visual cortex in MDD, which could pave the way for specific clinical interventions.
- Open Access
- 20 January 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 742959
Surgical vs. Conservative Management for Lobar Intracerebral Hemorrhage, a Meta-Analysis of Randomized Controlled Trials
Background: Outcomes regarding the conventional surgical and conservative treatment for the lobar intracerebral hemorrhage (ICH) have not been previously compared. The current meta-analysis was designed to review and compile the evidence regarding the management of patients with lobar intracerebral hemorrhage.Methods: Online electronic databases, including PubMed, Embase, Medline, Cochrane Library, and Google Scholar, were searched for randomized controlled trials (RCTs). Studies were selected on the basis of the inclusion and exclusion criteria. Trials with CT-confirmed lobar intracerebral hemorrhage patients of which treatment regimen was started within 72 h following the stroke were included. Low quality trials were excluded. Death or dependence was defined as primary outcome and death at the end of the follow up was the secondary outcome.Results: One hundred five RCTs were screened and 96 articles were excluded on the basis of Nine articles were assessed for the eligibility and 7 trials were included that involved 1,102 patients. The Odds ratio (OR) for the primary outcome was 0.80 (95% CI, 0.62–1.04, p = 0.09) and for the secondary outcome was 0.79 (95%CI, 0.60–1.03, p = 0.09).Conclusion: Our findings suggested that surgical treatments did not significantly improve the functional outcome as compared with the conservative medical management for patients with lobar ICH.
- 20 January 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 742959
Open AccessSurgical vs. Conservative Management for Lobar Intracerebral Hemorrhage, a Meta-Analysis of Randomized Controlled Trials
Background: Outcomes regarding the conventional surgical and conservative treatment for the lobar intracerebral hemorrhage (ICH) have not been previously compared. The current meta-analysis was designed to review and compile the evidence regarding the management of patients with lobar intracerebral hemorrhage.Methods: Online electronic databases, including PubMed, Embase, Medline, Cochrane Library, and Google Scholar, were searched for randomized controlled trials (RCTs). Studies were selected on the basis of the inclusion and exclusion criteria. Trials with CT-confirmed lobar intracerebral hemorrhage patients of which treatment regimen was started within 72 h following the stroke were included. Low quality trials were excluded. Death or dependence was defined as primary outcome and death at the end of the follow up was the secondary outcome.Results: One hundred five RCTs were screened and 96 articles were excluded on the basis of Nine articles were assessed for the eligibility and 7 trials were included that involved 1,102 patients. The Odds ratio (OR) for the primary outcome was 0.80 (95% CI, 0.62–1.04, p = 0.09) and for the secondary outcome was 0.79 (95%CI, 0.60–1.03, p = 0.09).Conclusion: Our findings suggested that surgical treatments did not significantly improve the functional outcome as compared with the conservative medical management for patients with lobar ICH.
- Open Access
- 8 September 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 673703
Impact of COVID-19 on Acute Stroke Presentation in a Designated COVID-19 Hospital
Objectives: Thousands of designated COVID-19 hospitals have been set up in China to fight the ongoing COVID-19 pandemic. Anecdotal reports indicate a falling rate of acute stroke diagnoses in these hospitals during the COVID-19 period. We conducted an exploratory single-center analysis to estimate the change in acute stroke presentation at the designated COVID-19 hospitals.Methods: This retrospective observational study included all patients admitted to Yongchuan Hospital Affiliated to Chongqing Medical University with acute stroke between January 24 and March 10, 2020. Patient demographics, characteristics of the stroke, treatment details, and clinical outcomes were compared with those of patients admitted in the corresponding period in the year before (2019, “the pre-COVID-19 period”). Subgroup analysis was performed in the ischemic and hemorrhagic stroke groups.Results: A total of 110 patients presented with acute stroke symptoms during the COVID-19 pandemic, compared with 173 patients in the pre-COVID-19 period. A higher proportion of stroke patients presented to the hospital via emergency medical services during the pandemic (48.2 vs. 31.8%, p = 0.006). There was a lower proportion of ischemic stroke patients (50.9 vs. 65.3%, p = 0.016) than in the preceding year. There were significantly fewer patients with 90-day modified Rankin Scale score ≥3 in the COVID-19 period compared with the pre-COVID-19 period (17.3 vs. 30.6%, p = 0.012). Among patients with ischemic stroke, the mean time from patient arrival to vessel puncture for emergency endovascular therapy in the COVID-19 period was shorter than that in the pre-COVID-19 period (109.18 ± 71.39 vs. 270.50 ± 161.51 min, p = 0.002). Among patients with hemorrhagic stroke, the rate of emergency surgical operation in the COVID-19 period was higher than that in the pre-COVID-19 period (48.1 vs. 30.0%, p = 0.047). The mean time from patient arrival to emergency surgical operation (15.31 ± 22.89 vs. 51.72 ± 40.47 min, p = 0.002) was shorter in the COVID-19 period than in the pre-COVID-19 period.Conclusions: Although fewer acute stroke patients sought medical care in this designated COVID-19 hospital during the COVID-19 pandemic, this type of hospital was more efficient for timely treatment of acute stroke. Recognizing how acute strokes presented in designated COVID-19 hospitals will contribute to appropriate adjustments in strategy for dealing with acute stroke during COVID-19 and future pandemics.
- 8 September 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 673703
Open AccessImpact of COVID-19 on Acute Stroke Presentation in a Designated COVID-19 Hospital
Objectives: Thousands of designated COVID-19 hospitals have been set up in China to fight the ongoing COVID-19 pandemic. Anecdotal reports indicate a falling rate of acute stroke diagnoses in these hospitals during the COVID-19 period. We conducted an exploratory single-center analysis to estimate the change in acute stroke presentation at the designated COVID-19 hospitals.Methods: This retrospective observational study included all patients admitted to Yongchuan Hospital Affiliated to Chongqing Medical University with acute stroke between January 24 and March 10, 2020. Patient demographics, characteristics of the stroke, treatment details, and clinical outcomes were compared with those of patients admitted in the corresponding period in the year before (2019, “the pre-COVID-19 period”). Subgroup analysis was performed in the ischemic and hemorrhagic stroke groups.Results: A total of 110 patients presented with acute stroke symptoms during the COVID-19 pandemic, compared with 173 patients in the pre-COVID-19 period. A higher proportion of stroke patients presented to the hospital via emergency medical services during the pandemic (48.2 vs. 31.8%, p = 0.006). There was a lower proportion of ischemic stroke patients (50.9 vs. 65.3%, p = 0.016) than in the preceding year. There were significantly fewer patients with 90-day modified Rankin Scale score ≥3 in the COVID-19 period compared with the pre-COVID-19 period (17.3 vs. 30.6%, p = 0.012). Among patients with ischemic stroke, the mean time from patient arrival to vessel puncture for emergency endovascular therapy in the COVID-19 period was shorter than that in the pre-COVID-19 period (109.18 ± 71.39 vs. 270.50 ± 161.51 min, p = 0.002). Among patients with hemorrhagic stroke, the rate of emergency surgical operation in the COVID-19 period was higher than that in the pre-COVID-19 period (48.1 vs. 30.0%, p = 0.047). The mean time from patient arrival to emergency surgical operation (15.31 ± 22.89 vs. 51.72 ± 40.47 min, p = 0.002) was shorter in the COVID-19 period than in the pre-COVID-19 period.Conclusions: Although fewer acute stroke patients sought medical care in this designated COVID-19 hospital during the COVID-19 pandemic, this type of hospital was more efficient for timely treatment of acute stroke. Recognizing how acute strokes presented in designated COVID-19 hospitals will contribute to appropriate adjustments in strategy for dealing with acute stroke during COVID-19 and future pandemics.
- 1 September 2020
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 196, 106009
Prognostic value of cerebral infarction coefficient in patients with massive cerebral infarction
- 1 September 2020
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 196, 106009
Prognostic value of cerebral infarction coefficient in patients with massive cerebral infarction
- 26 March 2020
- Published by Springer Nature in Neurocritical Care
- Vol. 33 (3) , 732-739
Intraventricular Hemorrhage Growth: Definition, Prevalence and Association with Hematoma Expansion and Prognosis
Background/Objectives The objective of this study is to propose a definition of intraventricular hemorrhage (IVH) growth and to investigate whether IVH growth is associated with ICH expansion and functional outcome. Methods We performed a prospective observational study of ICH patients between July 2011 and March 2017 in a tertiary hospital. Patients were included if they had a baseline CT scan within 6 h after onset of symptoms and a follow-up CT within 36 h. IVH growth was defined as either any newly occurring intraventricular bleeding on follow-up CT scan in patients without baseline IVH or an increase in IVH volume ≥ 1 mL on follow-up CT scan in patients with initial IVH. Poor outcome was defined as modified Rankin Scale score of 3–6 at 90 days. The association between IVH growth and functional outcome was assessed by using multivariable logistic regression analysis. Results IVH growth was observed in 59 (19.5%) of 303 patients. Patients with IVH growth had larger baseline hematoma volume, higher NIHSS score and lower GCS score than those without. Of 44 patients who had concurrent IVH growth and hematoma growth, 41 (93.2%) had poor functional outcome at 3-month follow-up. IVH growth (adjusted OR 4.15, 95% CI 1.31–13.20; P = 0.016) was an independent predictor of poor functional outcome (mRS 3–6) at 3 months in multivariable analysis. Conclusion IVH growth is not uncommon and independently predicts poor outcome in ICH patients. It may serve as a promising therapeutic target for intervention.
- 26 March 2020
- Published by Springer Nature in Neurocritical Care
- Vol. 33 (3) , 732-739
Intraventricular Hemorrhage Growth: Definition, Prevalence and Association with Hematoma Expansion and Prognosis
Background/Objectives The objective of this study is to propose a definition of intraventricular hemorrhage (IVH) growth and to investigate whether IVH growth is associated with ICH expansion and functional outcome. Methods We performed a prospective observational study of ICH patients between July 2011 and March 2017 in a tertiary hospital. Patients were included if they had a baseline CT scan within 6 h after onset of symptoms and a follow-up CT within 36 h. IVH growth was defined as either any newly occurring intraventricular bleeding on follow-up CT scan in patients without baseline IVH or an increase in IVH volume ≥ 1 mL on follow-up CT scan in patients with initial IVH. Poor outcome was defined as modified Rankin Scale score of 3–6 at 90 days. The association between IVH growth and functional outcome was assessed by using multivariable logistic regression analysis. Results IVH growth was observed in 59 (19.5%) of 303 patients. Patients with IVH growth had larger baseline hematoma volume, higher NIHSS score and lower GCS score than those without. Of 44 patients who had concurrent IVH growth and hematoma growth, 41 (93.2%) had poor functional outcome at 3-month follow-up. IVH growth (adjusted OR 4.15, 95% CI 1.31–13.20; P = 0.016) was an independent predictor of poor functional outcome (mRS 3–6) at 3 months in multivariable analysis. Conclusion IVH growth is not uncommon and independently predicts poor outcome in ICH patients. It may serve as a promising therapeutic target for intervention.